Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -87.12% is 43% above its 4-year average of -151.56%, near the high end of its 4-year range (-409.40%–-15.63%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.99% below its 12-month average of -79.93%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -87.12%.
RETURN ON EQUITY (ROE)
-87.12%
RETURN ON EQUITY (ROE) AVG TTM
-79.93%
RETURN ON EQUITY (ROE) AVG 3Y
-185.75%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-8.99%
CURRENT VS 3Y AVG
+53.10%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-107.37%
vs the sector median at left
Cardio Diagnostics Holdings, Inc.
Market Cap
$5.92M
Return on Equity (ROE)
-87.12%
TTM Avg
-79.93%
3Y Avg
-185.75%
5Y Avg
N/A
Market Cap
$5.89M
Return on Equity (ROE)
-34.33%
TTM Avg
-90.47%
3Y Avg
-81.08%
5Y Avg
-76.07%
Market Cap
$5.83M
Return on Equity (ROE)
-111.42%
TTM Avg
-84.56%
3Y Avg
-107.54%
5Y Avg
-308.31%
Market Cap
$5.82M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
Market Cap
$6.11M
Return on Equity (ROE)
-59.21%
TTM Avg
-23.87%
3Y Avg
-948.19%
5Y Avg
-660.49%
Market Cap
$5.73M
Return on Equity (ROE)
105.35%
TTM Avg
0.10%
3Y Avg
-37.77%
5Y Avg
-33.57%
Market Cap
$5.70M
Return on Equity (ROE)
-76.07%
TTM Avg
-61.76%
3Y Avg
-59.53%
5Y Avg
-66.20%
Market Cap
$5.63M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
Market Cap
$6.28M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | $5.92M | -87.12% | -79.93% | -185.75% | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.89M | -34.33% | -90.47% | -81.08% | -76.07% |
| Lucyd, Inc (LUCY)vs › | $5.83M | -111.42% | -84.56% | -107.54% | -308.31% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | -92.44% | -28.72% | 10.69% | 23.75% |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | -59.21% | -23.87% | -948.19% | -660.49% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.73M | 105.35% | 0.10% | -37.77% | -33.57% |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | -76.07% | -61.76% | -59.53% | -66.20% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -92.08% | -1221.97% | -730.41% | -532.44% |
| Femasys Inc. (FEMY)vs › | $6.28M | -304.78% | -566.96% | -321.57% | -251.82% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -163.18% | -235.11% | -195.15% | -161.13% |
ROE
-87.1%
ROA
-81.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -87.12% |
| 2026-03-31 | -74.70% |
| 2025-12-31 | -93.19% |
| 2025-09-30 | -80.38% |
| 2025-06-30 | -64.27% |
| 2025-03-31 | -51.46% |
| 2024-12-31 | -87.71% |
| 2024-09-30 | -223.89% |
| 2024-06-30 | -285.37% |
| 2024-03-31 | -378.94% |
| 2023-12-31 | -283.18% |
| 2023-09-30 | -409.40% |
| 2023-06-30 | -295.15% |
| 2023-03-31 | -157.90% |
| 2022-12-31 | -108.35% |
| 2022-09-30 | -25.84% |
| 2022-06-30 | -15.63% |
| 2022-03-31 | -98.99% |
| 2021-12-31 | -58.09% |
